



In re Application of: Furth et al.
 Application No. 10/037,616
 Filed: January 2, 2002
 For: TARGETING GENE EXPRESSION TO LIVING TISSUE USING JET INJECTION

PATENT
 Attorney Docket No. 219034
 DHHS Ref. No. E-064-1992/0-US-05
 Date: 8/4/2003

Mail Stop AF
 COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, VA 22313-1450

RECEIVED
 AUG 11 2003
 TECH CENTER 1600/2900

Sir:

Transmitted herewith is an Amendment and Response to Office Action in the subject application.

- ☐ Applicants claim small entity status of this application under 37 CFR 1.27.
- ☒ Petition for Extension of Time
- ☐ Applicants petition for a one-month extension of time under 37 CFR 1.136, the fee for which is \$110.00 (enclosed).
- ☒ Applicants believe that no petition for an extension of time is necessary. However, to the extent that such petition is deemed necessary, Applicants hereby petition for a sufficient extension of time to render the present submission timely. Please charge Deposit Account No. 12-1216 for the appropriate petition fee.
- ☒ No additional claim fee is required.
- ☒ Other: Journal Abstract

The claim fee has been calculated as shown below:

					SMALL ENTITY		OTHER THAN A SMALL ENTITY		
CLAIMS REMAINING AFTER AMENDMENT			HIGHEST NUMBER PREVIOUSLY PAID FOR	EXTRA CLAIMS PRESENT	RATE	ADDIT. CLAIM FEE	RATE	ADDIT. CLAIM FEE	
TOTAL		0	MINUS	0	=0	x 9=	\$	x 18=	\$0.00
INDEPENDENT		0	MINUS	0	=0	x 42=	\$	x 84=	\$0.00
<input type="checkbox"/>	FIRST PRESENTATION OF MULTIPLE CLAIM					+ 140=	\$	+ 280=	\$
						TOTAL	\$	TOTAL	\$0.00

- ☐ Please charge my Deposit Account No. 12-1216 in the amount of \$110.00. A duplicate copy of this sheet is attached.
- ☒ The Commissioner is hereby authorized to charge any deficiencies in the following fees associated with this communication or credit any overpayment to Deposit Account No. 12-1216. A duplicate copy of this sheet is attached.
- ☒ Any filing fees under 37 CFR 1.16 for the presentation of extra claims.
- ☒ Any patent application processing fees under 37 CFR 1.17.

Respectfully submitted,

LEYDIG, VOIT & MAYER, LTD.

By

Carol Larcher
 Carol Larcher, Reg. No. 35,243

Leydig, Voit & Mayer, Ltd.
 Two Prudential Plaza, Suite 4900
 180 North Stetson
 Chicago, Illinois 60601-6780
 (312) 616-5600 (telephone)
 (312) 616-5700 (facsimile)
 M:\Clients\NIH\Amd\219034 Amendment RFOA Transmittal.doc



RESPONSE UNDER 27 CFR 1.116
EXPEDITED PROCEDURE
EXAMINING GROUP 1636

PATENT
Attorney Docket No. 219034
DHHS Reference No. E-064-1992/0-US-05

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Furth et al.

Application No. 10/037,616

Art Unit: 1636

Filed: January 2, 2002

Examiner: J. Ketter

For: TARGETING GENE EXPRESSION TO
LIVING TISSUE USING JET
INJECTION


RECEIVED
AUG 11 2003
TECH CENTER 1600/2900

AMENDMENT AND RESPONSE TO FINAL OFFICE ACTION

Mail Stop AF
Commissioner for Patents
P.O. Box 1450
Arlington, VA 22313-1450

Dear Sir:

In response to the Final Office Action dated June 2, 2003, please consider the following remarks.

CERTIFICATE OF MAILING OR TRANSMISSION UNDER 37 CFR 1.8			
I hereby certify that this Response to Final Office Action and all accompanying documents are, on the date indicated below, <input checked="" type="checkbox"/> being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Non-Fee Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or <input type="checkbox"/> being facsimile transmitted to the U.S. Patent and Trademark Office, Attention: Examiner J. Ketter, Art Unit 1636, Facsimile Number (703) 305-7939.			
Name (Print/Type)	Kathleen N. Grantz		
Signature		Date	August 4, 2003